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The national Targeted Lung Health Checks programme: 
Focusing on the lungs does not mean missing adrenal lesions
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Recently, the UK’s national Targeted Lung Health Checks 
programme produced recommendations for the management 
of incidental findings identified during the scans performed as 
part of the lung cancer screening programme. We identified 
significant discrepancies between the recommendations for 
adrenal incidentaloma management and those currently 
implemented into UK practice (2016 European Society of 
Endocrinology guidelines).
This may create conflict and confusion between referrers 
(respiratory clinicians) and receivers (endocrinologists), 
with potential negative impact on patients, delay and 
inefficient use of resources. We also address the potential cost 
implications of adopting a more vigilant approach as advised 
by the European Society of Endocrinology.
Urgent multidisciplinary and unified guidelines should be 
established in the interest of clinical- and cost-effectiveness.
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The NHS Long Term Plan included the target that ‘by 2028, the 
proportion of cancers diagnosed at stages 1 and 2 will rise from 
around half now to three-quarters of cancer patients’.1 As a result, 
the national Targeted Lung Health Checks programme, offers the 
opportunity of a lung health check to individuals aged 55–74 years 
who have ever smoked.2 The programme recently published 
its quality assurance standards, including action on incidental 
findings.2
Among those, adrenal incidental findings were included with the 
advice that, apart from lesions smaller than 1 cm, all other lesions 
require review at the ‘screening review meeting’. When reviewed 
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in the meeting, the recommendation is that lesions <1 cm or 
<10 Hounsfield units (HU), no further action is required. For lesions 
1–4 cm and >10 HU, no action is warranted but for a repeat scan in 
12 months. Lesions >4 cm need to be referred to endocrinology.2
These recommendations contradict the recently published European 
Society of Endocrinology (ESE) guidelines that are widely used in the 
UK.3 According to these, all patients with adrenal incidentaloma >1 
cm should have excess cortisol and catecholamines investigated (via 
overnight dexamethasone suppression test together with plasma 
metanephrines or urinary fractionated metanephrines). In addition, 
patients with hypertension or unexplained hypokalaemia will require 
aldosterone excess explored with aldosterone:renin ratio.  
Furthermore, measurement of sex hormones and steroid precursors is 
recommended if there are manifestations suggestive of adrenocortical 
cancer (clinical or radiological).3
Furthermore, the ESE recommends that the density and 
homogeneity of an adrenal lesion is assessed on non-contrast 
computed tomography (CT). If the lesion is lipid-rich (<10 HU) and 
is <4 cm in size, then no further imaging is required. However, if 
indeterminate on non-contrast CT (ie >10 HU), with no evidence 
of hormone over-production, a multidisciplinary team (MDT) 
meeting should decide, with the clinical context, whether to 
proceed with further imaging, arrange interval non-contrast CT 
or magnetic resonance imaging (MRI) in 6–12 months or refer for 
surgery.3
Accordingly, the NHS lung cancer programme risks overlooking 
whether lesions between 1–4 cm are associated with hormone 
excess, or indeed whether they are malignant (either primary 
or metastatic). In lung cancer patients, 4% had adrenal 
incidentalomas, with almost three-quarters being metastatic; 
only ∼25% were benign adenomas.4 Based on this, lesions >1 cm 
with density >10 HU should not be left merely to have repeat CT 
in 12 months. Expert adrenal MDTs could have an important role 
of providing recommendations on which patients should undergo 
further investigations in an endocrine centre. Establishing tumour 
functionality, together with considering the risk of malignancy in 
this category (1–4 cm with HU of >10) is crucial. In addition to 
the potential for these missed cases, the conflicting guidance will 
create confusion in clinical practice.
While more than 80% of adrenal incidentalomas are non-
functioning, the commonest functional abnormality is excess 
cortisol in >10% of cases.3 A 15-year retrospective study 
demonstrated that, even with subclinical hypercortisolism, 
adrenal incidentalomas patients had an increased cardiovascular 
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study revealed that the frequency of adrenal incidentalomas was 
7.3%, significantly higher than previous reports. With multivariate 
regression analysis, diabetes was significantly associated with 
the presence of adrenal incidentalomas (p=0.003). Failure to 
suppress in overnight dexamethasone suppression test was 
observed in 50% of patients; again, significantly higher than 
the previously reported incidence of ∼10%. The study did not 
have ascertainment bias as the prospectively drawn adrenal 
incidentalomas cohort had the same risk of diabetes similar to 
the general population.6 While less common, hyperaldosteronism 
and particularly phaeochromocytoma have serious morbidity 
and mortality implications, so cannot be ignored. They could be 
associated with lesions <4 cm.
We want to emphasise that this will apply to individuals who 
have screened negative for lung cancer. The management would 
potentially be different if lung cancer is detected. In these cases, 
close interaction between the lung and adrenal MDTs will be 
required.
Paradoxically, it would be important to recognise that the 
caseload generated through this programme is not insignificant. 
This proactive programme is targeting individuals aged 
55 years and above where adrenal incidentaloma prevalence 
rises, from being rare in children to ∼3% at 50 years and 10% 
in the elderly.7 Planning for this increased workload should 
be considered from the outset, acknowledging that current 
guidelines on adrenal incidentalomas rely mostly on large case 
series with limited systematic data and cost-effectiveness 
analysis. To address this gap, we have recently developed a 
cost-effectiveness tool for adrenal incidentaloma management.8 
We have initiated discussions with the lung cancer screening 
programme to support their efforts in establishing a clinically- 
and cost-effective strategy to address adrenal incidentalomas. 
Such initiatives are essential if the NHS is to address this potential 
clinical risk. ■
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